의학, 의술, 의도를 함양하여 실천하는 지성인 양성!

한의과대학

교수 경력 및 연구업적

박선동 교수님

orient202005041527155eafb5c357163.jpg

학력

  • 1985. 동국대학교 한의과대학 한의학사
  • 1987. 동국대학교 한의과대학 한의학 석사
  • 1992. 동국대학교 한의과대학 한의학 박사

경력

  • 1993~1994. 동국대학교 한의과대학 전임강사
  • 1994~1998. 동국대학교 한의과대학 조교수
  • 1998~2003. 동국대학교 한의과대학 부교수
  • 2003~ 현재 . 동국대학교 한의과대학 교수

수상 및 활동사항

  • 대통령 표창 (2018)
  • 동국대학교 한의과대학 학장 (2013~2015)
  • 건강보험심사평가원 약제급여평가위원회 한약제제소위원회 위원
  • 식품의약품안전처 건강식품심의위원회 위원
  • 보건복지부 한의약육성발전계획 위원회 위원
  • 대한한의학방제학회 이사

연구업적

  • Polygonum aviculare L. extract reduces fatigue by inhibiting neuroinflammation in restraint-stressed mice. Phytomedicine. 2018.
  • Akebia quinata Decaisne aqueous extract acts as a novel anti fatigue agent in mice exposed to chronic restraint stress. Journal of Ethnopharmacology. 2018.
  • Antioxidant and anti-inflammatory effects of herbal formula SC-E3 in lipopolysaccharide stimulated RAW264.7 macropharges. Evidence-Based Complementary and Alternative Medicine. 2017.
  • Herbal formula SC-E1 supresses lipopolysaccharide-stimulated inflammatory responses through activation of Nrf/HO-1 signaling pathway in RAW264.7 macrophages. BMC Complementary and Alternative Medicine. 2017.
  • Saeng-Kankunbi-Tang ( 生肝健脾汤 ) protects liver against oxidative damage through activation of ERK/Nrf2 pathway. Chinese Journal of Integrative Medicine. 2017.

김영우 교수님

경력 및 활동사항

  • 식품의약품안전처 한약정책과 과장 ( 서기관 )
  • 대한한의학방제학회지 편집위원장
  • 대한 약학회 학술상 (2011)
  • ISO TC 215, TC 249 국가 기술 표준 전문위원 (EMR/ 의료정보 / 한의약품)
  • 한국의약품안전관리원 의약품부작용피해구제위원회 위원

EDUCATION & EXPERIENCE

  • Ph.D. College of Pharmacy, Seoul National University (Molecular Pharmacology)
  • Ph.D. College of Korean Medicine, Dongguk University (Herbal Formula)
  • Korea-EU Research Fellowship (Immunology, Virgen Hospital de la Arrixaca, Spain)

RESEARCH INTERESTS & RELATED SKILLS

  • Study of biomarkers for diagnosis of the disease in Korean Medicine
  • Optimization of herbal formula and herbal pharmaceutics for the treatment of chronic disease
  • Identification of molecular targets (i.e. hepatitis, ASH, NASH, NAFLD) by generation of liver diseases animal models (i.e. fibrosis and cancer) and metabolic diseases models (i.e. high-fat diet, Lieber-De Carli diet, ob/ob , db/db mice)

연구업적

  • Lee EH, Park KI, Kim YW*. Liquiritigenin inhibits hepatic fibrogenesis and TGF- β 1/Smad with Hippo/YAP signal. Phytomedicine. 2019;62
  • Kim KY, Lee SG, Kim YW*. Salinomycin ameliorates oxidative hepatic damage through AMP-activated protein kinase, facilitating autophagy. Toxicology and applied pharmacology. 2018;360:141-149.
  • Lee JH, Baek SY, Kim YW*. Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase. Chem Biol Interact. 2018;289:68-74.
  • Jung EH, Lee JH, Kim SC, Kim YW* AMPK activation by liquiritigenin inhibited oxidative hepatic injury and mitochondrial dysfunction induced by nutrition deprivation as mediated with induction of farnesoid X receptor. Eur J Nutr. 2017;56:635-647.
  • Lee JH, Jung JY, Kim YW*. Combination of honokiol and magnolol inhibits hepatic steatosis through AMPK-SREBP-1   c pathway. Exp Biol Med 2015;240:508-518.